PHARMASPIRE - Volume 15, Issue 03, 2023 , July- September
Pages: 170-176
Date of Publication: 11-Dec-2023
Print Article
Download XML Download PDF
Insight on development and management of neuropathic pain
Author: Mandeep Kaur, Prabha Rajput
Category: Pharmacology
Abstract:
Diabetic peripheral neuropathy (DPN) impacts up to 50% of diabetic people and is a major cause of illness and death. Its neuropathic symptoms, which can be painful, and insensitivity increase the risk of burns, injuries, and foot ulcers. Several recent studies have identified several risk factors for developing DPN, including obesity, poor glycemic control, diabetes duration, hyperlipidemia, impaired insulin signaling, and lipid oxidation and inflammation. Inspection of the lower limbs is necessary for the diagnosis. Anticonvulsant or tricyclic medications, which are typically used, may be needed. Peripheral neuropathy patients should be treated by a podiatrist and given preventative education since they risk developing insensate foot ulcers. A multidisciplinary approach to preventing and managing foot problems, promptly diagnosing and treating neuropathic pain, and controlling specific cardiometabolic objectives should all be included in treating patients with DPN. The concept of categorizing patients based on different aspects of their pain to enhance analgesic response is being researched, and new drugs are being developed to manage painful DPN.
Keywords: Cardiometabolic, Hyperglycemia, Hyperlipidemia, Paresthesia, Sensorimotor polyneuropathy
DOI: 10.56933/Pharmaspire.2023.15127
DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15127
References:
1. Wang Z, Peng S, Zhang H, Sun H, Hu J. Gait parameters and peripheral neuropathy in patients with diabetes: A meta-analysis. Front Endocrinol (Lausanne) 2022;13:891356.
2. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012;28:8-14.
3. Roth B, Schiro DB, Ohlsson B. Diseases which cause generalized peripheral neuropathy: A systematic review. Scand J Gastroenterol 2021;56:1000-10.
4. Selvarajah D, Sloan G, Tesfaye S. Diabetic neuropathy. In: The Foot in Diabetes. United States: John Wiley & Sons Ltd.; 2020. p. 89-103.
5. Borges A, Casselman J. Imaging the trigeminal nerve. Eur J Radiol 2010;74:323-40.
6. Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 2019;19:86.
7. Fang F, Wang J, Wang YF, Peng YD. Microangiopathy in diabetic polyneuropathy revisited. Eur Rev Med Pharmacol Sci 2018;22:6456-62.
8. Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. J Diabetes Investig 2018;9:1239-54.
9. Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, et al. Diabetic peripheral neuropathy: Advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 2019;7:938-48.
10. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: Epidemiology, diagnosis, and pharmacotherapy. Clin Ther 2018;40:828-49.
11. Millington JT, Ellenzweig J. The comprehensive therapy of diabetic foot ulcers. Compr Ther 2005;31:50-8.
12. American Diabetes Association. 9. Microvascular complications and foot care. Diabetes Care 2016;39:S72-80.
13. Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Med 2016;33:1466-76.
14. Fonseca VA. Identification and treatment of prediabetes to prevent progression to Type 2 diabetes. Clin Cornerstone 2008;9:51-61.
15. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in Type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010;376:419-30.
16. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:721-7.
17. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-84.
18. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50.
19. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes--2019. Diabetes Care 2019;42:S13-28.
20. Green AQ, Krishnan S, Finucane FM, Rayman G. Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care 2010;33:174-6.
21. Feldman EL, Nave KA, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron 2017;93:1296-313.
22. Ozair M, Noor S, Raghav A, Siddiqi SS, Chugtai AM, Ahmad J. Prevalence of thyroid disorders in North Indian Type 2 diabetic subjects: A cross sectional study. Diabetes Metab Syndr 2018;12:301-4.
23. Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G, et al. Oxidative stress in obesity: A critical component in human diseases. Int J Mol Sci 2014;16:378-400.
24. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol 2012;11:521-34.
25. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med 2011;15:1807-21.
26. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and Type 2 diabetes. Int J Biol Sci 2018;14:1483-96.
27. Clemens A, Siegel E, Gallwitz B. Global risk management in Type 2 diabetes: Blood glucose, blood pressure, and lipids-update on the background of the current guidelines. Exp Clin Endocrinol Diabetes 2004;112:493-503.
28. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol 2021;17:400-20.
29. Vincent AM, Hayes JM, McLean LL, VivekanandanGiri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: The role of oxLDL/LOX-1. Diabetes 2009;58:2376-85.
30. Gonçalves NP, Vægter CB, Andersen H, Østergaard L, Calcutt NA, Jensen TS. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol 2017;13:135-47.
31. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006;212:167-78.
32. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011;7:573-83.
33. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.
34. Gholami F, Nikookheslat S, Salekzamani Y, Boule N, Jafari A. Effect of aerobic training on nerve conduction in men with Type 2 diabetes and peripheral neuropathy: A randomized controlled trial. Neurophysiol Clin 2018;48:195-202.
35. Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol (Lausanne) 2021;12:671257.
36. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: Consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27:629-38.
37. Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009;3:136-43.
38. Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2011;2:33-42.
39. Kanwugu ON, Glukhareva TV, Danilova IG, Kovaleva EG. Natural antioxidants in diabetes treatment and management: Prospects of astaxanthin. Crit Rev Food Sci Nutr 2022;62:5005-28.
40. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet 2007;369:1016-26.
41. Krishnan ST, Rayman G. New treatments for diabetic neuropathy: Symptomatic treatments. Curr Diab Rep 2003;3:459-67.
42. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002;103:311-21.
43. Litchy W, et al. Diabetic Peripheral Neuropathy (DPN) Assessed by Neurological Examination (NE) and Composite Scores (CS) is Improved with LY333531 Treatment. Diabetes. Vol. 51. 1660 DUKE ST, Alexandria, VA 22314 USA: American Diabetes Association; 2002
|
